The pyroptosis-related risk signature (PRRS) established in the present study involved genes from canonical pathways, such as MEFV and NLRC4; genes from non-canonical pathways, such as CASP5, GZMA, and GZMB; gene-coded pyroptosis executioner, such as GSDMB; and genes involved in pyroptosis regulation, such as STAT3 and SARM. Therefore, this signature may provide a more comprehensive understanding of pyroptosis than previous pyroptosis-related signatures identified in glioma (56–58). This evidence concerns the gene CASP5 and central nervous system cancer.